Effective Screening and Testing for Tuberculosis Act

This bill requires tissue banks and manufacturers of human cell/tissue products to screen donors for both active and latent tuberculosis infections before tissue use. It mandates new FDA regulations (to be proposed within one year) requiring these facilities to implement TB screening and testing, with final rules set for promulgation within three months after public comments. The law updates existing FDA guidance on tissue safety within six months and treats innovative TB screening tests as "breakthrough devices" for faster approval. It applies directly to facilities handling tissue donations, aiming to prevent disease transmission through transplanted tissues, and uses existing funding without new appropriations.